Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices
In conclusion, in Germany pts with CML are routinely monitored by qPCR and good responses are achieved in the majority. Treatment changes are mainly due to adverse events rather than suboptimal responses. (Source: Annals of Hematology)
Source: Annals of Hematology - March 12, 2024 Category: Hematology Source Type: research
Secondary hemophagocytic lymphohistiocytosis in pediatric patients with visceral leishmaniasis and Epstein-Barr virus infection
In this study, we aimed to provide insights for early diagnosis and improve outcomes in pediatric patients with VL-HLH. We retrospectively analyzed the clinical and laboratory data of 10 pediatric patients with VL-HLH and 58 pediatric patients with Epstein –Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH). The median time from symptom onset to cytopenia in patients with VL-HLH and EBV-HLH was 11 days (interquartile range, 7–15 days) and five days (interquartile range, 3.75–9.25 days) (P = 0.005). Both groups showed liver injury and increased lactate dehydrogenase levels; however the levels of as...
Source: Annals of Hematology - March 12, 2024 Category: Hematology Source Type: research
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group
This study was registered with ClinicalTrials.gov on Aug 4th, 2009, number NCT00954005. (Source: Annals of Hematology)
Source: Annals of Hematology - March 9, 2024 Category: Hematology Source Type: research
Incidence and reasons for discontinuation of first-line therapy in patients with multiple myeloma: results from a historical cohort, Brazil 2009 –2020
In conclusion, discontinuation of first-line therapy followed by second-line treatment occurred as likely as the discontinuation not followed by a subsequent line. (Source: Annals of Hematology)
Source: Annals of Hematology - March 9, 2024 Category: Hematology Source Type: research
Transformation risk and associated survival outcome of marginal zone lymphoma: A nationwide study
AbstractHistological transformation into an aggressive B-cell lymphoma indicates a poor survival outcome for patients with indolent marginal zone lymphoma (MZL), which has been less studied. Large-scale data with long-term follow-up to investigate MZL transformation is limited. Here, by reporting a US-Nationwide cohort of 30,619 MZL patients diagnosed between 2000 and 2019, we found that transformation occurred in 2.08% (N = 624) of MZL cases, with the transformation incidence of 3.1 per 1,000 person-years. Advanced Ann Arbor stage, nodal MZL (NMZL) and splenic MZL (SMZL) were associated with an elevated risk of transf...
Source: Annals of Hematology - March 9, 2024 Category: Hematology Source Type: research
Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
(Source: Annals of Hematology)
Source: Annals of Hematology - March 9, 2024 Category: Hematology Source Type: research
Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan
In this study we show the potential of an individualized dosing regimen of pegcetacoplan with can improve patient friendliness in approximately 30% of the patients and im prove therapy in approximately 2% of the patients at slightly reduced costs. (Source: Annals of Hematology)
Source: Annals of Hematology - March 8, 2024 Category: Hematology Source Type: research
A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors
In this study, a pharmacovigilance analysis was conducted using the FDA Adverse Event Reporting System database. Suspected adverse events linked to HDAC inhibitors were detected through various statistical methodologies, including reporting odds ratio, proportional reporting ratio, information component, and Empirical Bayes Geometric Mean. Our study findings have illuminated that, among the total reported cases examined, gastrointestinal disorders accounted for 13% patients of the cohort, while lymphatic system disorders comprised 8% cases of the cohort, all of which manifested as adverse events induced by HDAC inhibitors....
Source: Annals of Hematology - March 8, 2024 Category: Hematology Source Type: research
Validation of a Stenotrophomonas maltophilia bloodstream infection prediction score in the hematologic malignancy population
AbstractStenotrophomonas maltophilia (SM) bloodstream infections (BSIs) contribute to significant mortality in hematologic malignancy (HM) and hematopoietic stem cell transplantation (HSCT) patients. A risk score to predict SM BSI could reduce time to appropriate antimicrobial therapy (TTAT) and improve patient outcomes. A single center cohort study of hospitalized adults with HM/HSCT was conducted. Patients had ≥ 1 blood culture with a Gram-negative (GN) organism. A StenoSCORE was calculated for each patient. The StenoSCORE2 was developed using risk factors for SM BSI identified via logistic regression. Receiver op...
Source: Annals of Hematology - March 8, 2024 Category: Hematology Source Type: research
Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia
In conclusion, EM was frequently mutated in adult ALL and was characterized by poor response to induction therapy and inferior clinical outcomes. (Source: Annals of Hematology)
Source: Annals of Hematology - March 7, 2024 Category: Hematology Source Type: research
Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma
ConclusionsOur meta-analysis offers a comprehensive view of Len and Dara's impacts on hematopoietic stem cell collection and reconstitution in multiple myeloma. Len usage could lead to reduced stem cell collection, counteracted by plerixafor mobilization. Dara usage could result in diminished stem cell collection and delayed platelet engraftment. (Source: Annals of Hematology)
Source: Annals of Hematology - March 6, 2024 Category: Hematology Source Type: research
Acute myeloid leukemia with rare recurring translocations —an overview of the entities included in the international consensus classification
AbstractTwo different systems exist for subclassification of acute myeloid leukemia (AML); the World Health Organization (WHO) Classification and the International Consensus Classification (ICC) of myeloid malignancies. The two systems differ in their classification of AML defined by recurrent chromosomal abnormalities. One difference is that the ICC classification defines an AML subset that includes 12 different genetic abnormalities that occur in less than 4% of AML patients. These subtypes exhibit distinct clinical traits and are associated with treatment outcomes, but detailed description of these entities is not easil...
Source: Annals of Hematology - March 6, 2024 Category: Hematology Source Type: research
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study
AbstractWe conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, after a maximum follow-up of five years. Patients were included according to the French marketing authorization in 2016 (i.e. patients with relapsed or refractory CLL or to previously untreated CLL patients with deletion 17p and/or tumor protein p53 mutations unsuitable for chemoimmunotherapy) and could have initiated ibrutinib more than 30 days prior their enrolment in the study (i.e. retrospective patients) or between 30 days before and 14 d...
Source: Annals of Hematology - March 6, 2024 Category: Hematology Source Type: research
Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenstr öm macroglobulinemia
AbstractWaldenstr öm macroglobulinemia (WM) is a type of B-cell lymphoma that produces IgM. Our study aimed to investigate the role of CXCL13, a chemokine essential for B lymphocytes, in the evaluation of treatment response and prognosis in WM. We collected serum samples and clinical data from 72 WM patients, with 6 9 patients receiving systemic therapy and 3 patients opting not to receive treatment. Serum CXCL13 levels at baseline and after six months of treatments were measured by enzyme-linked immunosorbent assay. The median serum level of CXCL13 was 1 539.2 pg/ml (range 10.0–21 389.9) at baseline and sig nificantly...
Source: Annals of Hematology - March 6, 2024 Category: Hematology Source Type: research
Allogeneic stem cell transplantation is still a highly curative therapy in adults with philadelphia chromosome –positive acute lymphoblastic leukaemia
In conclusion, transplantation as a one-time procedure for adults with Ph + ALL patients remains important in countries lacking accessibility to third-generation TKIs or immunotherapies, regardless of the depth of the molecular response. (Source: Annals of Hematology)
Source: Annals of Hematology - March 5, 2024 Category: Hematology Source Type: research
